Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Advances in Bacteria and Cancer
share announcement

Advances in Bacteria and Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: 10 September 2024 | Viewed by 1538

Special Issue Editor

Dr. Alain P. Gobert

E-Mail Website
Guest Editor
Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, TN 37232-0252, USA
Interests: gastrointestinal inflammation; gastric cancer; colitis-associated carcinogenesis; colorectal cancer; polyamines; reactive aldehydes

Special Issue Information

Dear Colleagues,

Emerging evidence has pointed towards the extensive involvement of bacteria in cancer biology. They may regulate carcinogenesis, cancer progression, and metastasis, as well as response to treatments. This occurs through a direct effect on oncogenic signaling, or indirectly by modulating host immunes and/or metabolic responses. This Special Issue, “Advances in Bacteria and Cancer”, focuses on the identification and implication of different bacterial communities, including, but not limited to, pathogens, resident microbiota, tumor-associated bacteria, or probiotics in cancer. We will publish original articles and reviews on all types of cancer. Multi-omics, mechanistic, pre-clinical, and clinical investigations are welcome in this Special Issue.

Dr. Alain P. Gobert
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pathogenic bacteria
  • microbiota
  • tumor-associated bacteria
  • probiotics
  • oncogenesis
  • metastasis
  • chemotherapy
  • cancerous cells
  • tumor microenvironment
  • cell signaling

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

14 pages, 1234 KiB  
Review
Bladder Cancer and Probiotics: What Do We Know So Far?
by Pedro Sánchez-Pellicer, Claudia Boix-Rodríguez, Adriana Hernández-Belmonte, Cristina de la Encarnación-Castellano, Alberto Mendiola-López, Eva Núñez-Delegido, Laura Navarro-Moratalla, Juan Agüera-Santos, Vicente Navarro-López and Juan Antonio Galán-Llopis
Cancers 2023, 15(23), 5551; https://doi.org/10.3390/cancers15235551 - 23 Nov 2023
Viewed by 1368
Abstract
Bladder cancer is around the 10th most diagnosed cancer, although has a considerable mortality. Recent research and new methodologies have discarded the historical dogma that the bladder (and urine) was sterile under normal conditions. Specifically, only a few studies have reported a detailed [...] Read more.
Bladder cancer is around the 10th most diagnosed cancer, although has a considerable mortality. Recent research and new methodologies have discarded the historical dogma that the bladder (and urine) was sterile under normal conditions. Specifically, only a few studies have reported a detailed analysis of the urinary microbiota in patients with bladder cancer, thus exhibiting a remarkable variability due to the low biomass of the urinary microbiota and the influence of many factors. Nevertheless, this research shows us signals that urinary microbiota is a factor to be considered in the pathophysiology of bladder cancer. More importantly, probiotics could be useful as an adjuvant therapy to reduce the recurrence rate or increase the disease-free period after surgery. In vitro studies and animal assays have shown promising results, but the research in this context has also been scarce, and only a few studies have been conducted in humans. In summary, there is little evidence of the possible beneficial effect of probiotics in controlling the overgrowth of genera that could be involved in the carcinogenesis of bladder cancer. This narrative review aims to compile all the evidence to date on the therapeutic potential of probiotics injected directly into the bladder or orally administered. Full article
(This article belongs to the Special Issue Advances in Bacteria and Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop